Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
CC transcript
GENEREX BIOTECHNOLOGY CORP (GNBT) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/17/2020 8-K/A Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "The Extension Agreement signed December 15, 2020",
"The Letter requesting more time for payment signed December 14, 2020"
08/21/2020 8-K/A Quarterly results
10/29/2019 8-K/A Quarterly results
06/05/2019 8-K/A Financial Statements and Exhibits
Docs: "Audited consolidated financial statements of Veneto Holdings, LLC as of September 30, 2018 and December 31, 2017 and for the nine months ended September 30, 2018 and the year ended December 31, 2017 including the report of Whitley Penn LLC on such audited financial statements",
"Unaudited pro forma condensed combined financial information as of and for the twelve-month period ended July 31, 2018"
03/25/2019 8-K/A Financial Statements and Exhibits
Docs: "Audited financial statements of Regentys Corporation for the years ended December 31, 2017 and 2016, including the report of BDO, USA LLP on such audited financial statements",
"Unaudited financial statements of Regentys Corporation for the nine (9) months ended September 30, 2018 and 2017",
"Unaudited pro forma condensed combined balance sheets as of October 31, 2018 and unaudited pro forma condensed statement of operations for the year ended July 31, 2018 and the three (3) months ended October 31, 2018"
03/22/2019 8-K/A Financial Statements and Exhibits
Docs: "Consent of Friedman LLP",
"Audited financial statements of Olaregen Therapeutix, Inc. for the period of inception (April 24, 2018) to June 30, 2018, including the report of Friedman LLP on such audited financial statements",
"Unaudited financial statements of Olaregen Therapeutix, Inc. for the three (3) months ended September 30, 2018",
"Unaudited pro forma combined balance sheets for the period ended October 31, 2018 and unaudited pro forma statement of operations for the year ended July 31, 2018 and the three (3) months ended October 31, 2018"
12/19/2018 8-K/A Financial Statements and Exhibits
Docs: "Unaudited pro forma condensed combined financial information as of and for the twelve-month period ended July 31, 2018",
"Unaudited consolidated financial statements for Veneto Holdings, LLC as of June 30, 2018 and December 31, 2017 and for the six months ended June 30, 2018 and 2017",
"Audited consolidated financial statements of Veneto Holdings, LLC for the years ended December 31, 2017 and 2016 including the report of Whitley Penn LLP on the 2017 audited financial statements"
12/12/2017 8-K/A Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Generex Announces Collaboration with Shenzhen BioScien Pharmaceuticals to Develop and Commercialize the AE37 Immunotherapeutic Vaccine for the Treatment of Prostate Cancer in China",
"License and Research Agreement between Shenzhen BioScien Pharmaceuticals Co., Ltd. and Antigen Express, Inc"
03/31/2017 8-K/A Form 8-K/A - Current report [Amend]
01/25/2017 8-K/A Form 8-K/A - Current report [Amend]
09/19/2008 8-K/A Form 8-K/A - Current report [Amend]
03/24/2004 8-K/A Form 8-K/A - Current report [Amend]
09/09/2003 8-K/A Form 8-K/A - Current report [Amend]
07/11/2003 8-K/A Form 8-K/A - Current report [Amend]
02/01/2001 8-K/A Form 8-K/A - Current report [Amend]
01/24/2001 8-K/A Form 8-K/A - Current report [Amend]
12/06/2000 8-K/A Form 8-K/A - Current report [Amend]
09/07/2000 8-K/A Form 8-K/A - Current report [Amend]

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy